Phase 1b study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.

Authors

E. Tan

National Cancer Centre, Singapore, Singapore

E. Tan , K. Park , W. T. Lim , M. Ahn , Q. S. Ng , J. S. Ahn , D. S. Tan , J. Sun , J. Jac , M. Han , F. C. Payumo , M. Credi , K. McKee , M. M. Cotreau , P. Bhargava , W. Slichenmyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

First Author: Julie E. Bauman

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.

First Author: T. Mok

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).

First Author: Rosario Garcia Campelo

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy.

First Author: Tomonori Hirashima